Barrier approach blood agents

This approach has been explored in attempts to treat progressive multifocal leukoencephalopathy/ a rapidly fatal disease caused by the JC virus and characterized by regions of central nervous system demyelination and markedly altered neuroglia. The virus is known to be sensitive in vitro to the action of cytosine arabi-noside (ARA-C) concentrations of 40 M (10 pg/mL) or more (12). Because the agent crosses the blood-brain barrier slowly Hall et al. (13) designed a study to test whether intraventricular/intrathecal administration of ARA-C could successfully treat JC virus in humans. ARA-C was administered as a bolus into the cerebrospinal fluid (CSF) space at the initial rate of 50 mg every 7 days. This ARA-C regimen was found to be... 

The dynamic first pass approach to CTP measnrement involves the IV administration of an intravascnlar contrast agent, which is tracked with serial imaging dnring its first circnlation throngh the brain tissne capillary bed. The main assnmption of dynamic first pass contrast-enhanced CTP models is that the perfnsion tracer is not diffnsible, neither metabolized nor absorbed by the tissue through which it traverses. This is certainly the case in a healthy hnman brain, however, breakdown of the blood-brain barrier (BBB) in infection, inflammation, or tnmor adds an additional level of complexity. When extensive BBB breakdown exists, leakage of... 

---